"RFK Jr. Says He's Not Anti-Vaccine, Sees Critical Role for Shots" - Bloomberg News

Benzinga4minutes ago

Sector Update: Health Care Stocks Edge Higher Pre-Bell Tuesday

MT Newswires22:16

Berenberg Bank Keeps Their Buy Rating on AstraZeneca (AZN)

TipRanks14:25 · Ratings

The new indication for Enhertu from Daiichi Sankyo/AstraZeneca (AZN.US) has been approved by the FDA.

On January 27, Daiichi Sankyo and AstraZeneca (AZN.US) announced that the supplemental Biological Product license application (sBLA) for Enhertu (fam-trastuzumab deruxtecan) was approved by the FDA for monotherapy in adult patients with inoperable or metastatic HER2-low expression (IHC 1+ or IHC 2+/ISH-) or HER2-ultra-low expression (IHC 0) breast cancer who have received at least one endocrine therapy in the metastatic setting.

Zhitong Finance10:32

AstraZeneca Receives FDA Approval for Enhertu Breast Cancer Treatment

WSJ07:59

AstraZeneca And Daiichi Sankyo's ENHERTU Approved In US As First HER2-directed Therapy For Patients With HER2-low Or HER2-ultralow Metastatic Breast Cancer Following Disease Progression After One Or More Endocrine Therapies

Benzinga07:05